Therefore, consistent with the pro-cancer effect of GSDMB in human HER2-positive carcinomas (Hergueta-Redondo et al., 2016; Molina-Crespo et al., 2019), the results in murine models show that GSDMB2 promotes tumor incidence specifically in the context of HER2/NEU-driven carcinogenesis. This evidence concerns the gene ERBB2 and cancer.